Technical analysis of Lantern Pharma Inc. (LTRN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer.
Price Performance
| 1 month | -32.54% |
| 3 months | -55.15% |
| Year-to-date | -43.89% |
| 1 year | -56.52% |
| 3 years | -56.52% |
| 5 years | -85.63% |
52-Week Range
| 52-week High | $4.70 |
| 52-week Low | $1.11 |
| Avg Volume (90d) | 188K |
Technical Indicators
| SMA 50 | $2.54 |
| SMA 200 | $2.88 |
| Beta | 1.75 |
| 30-day Volatility (annualised) | 50.8% |
| Price vs SMA 50 | -33.1% |
| Price vs SMA 200 | -40.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.01 | |
| 2025-11 | $3.62 | -9.7% |
| 2025-12 | $3.03 | -16.3% |
| 2026-01 | $3.15 | +4.0% |
| 2026-02 | $2.82 | -10.5% |
| 2026-03 | $1.37 | -51.4% |
| 2026-04 | $2.05 | +49.6% |
| 2026-05 | $3.59 | +75.1% |
| 2026-06 | $4.17 | +16.2% |
| 2026-07 | $2.63 | -36.9% |
| 2026-08 | $2.03 | -22.8% |
| 2026-09 | $1.70 | -16.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.93 |
| Market Cap | $25M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -7.45 |
| EV / EBITDA | -0.90 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.01 |
| Current Ratio | 1.96 |